When was Evofem founded?

Evofem was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is Evofem located?

Evofem is headquartered in San Diego, United States. It is registered at 12400 High Bluff Dr. Suite 600 San Diego, CA 92130.

How many employees does Evofem have?

As of Mar 01, 2026, the latest employee count at Evofem is 10 - 49.

Is Evofem a funded company?

Evofem is a funded company, having raised a total of $100M across 15 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 08, 2009.

When was the latest funding round of Evofem?

Evofem's latest funding was a $***** Post IPO round on Jun 26, 2025, with participation from 0 investor.

What is the annual revenue of Evofem?

Annual revenue of Evofem is between $10M and $50M as on Dec 31, 2025

Where does Evofem rank among its competitors?

Evofem ranks 3rd amongst 125 active competitors, of which 33 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Evofem?

Evofem's top competitors include BioNTech, Insmed and Basilea. Among them, Basilea secured the most recent funding round in May, 2026.

Evofem - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of sexual and reproductive health therapeutics. It offers two drug products which include PHEXXI vaginal gel that provides women with an in-the-moment contraceptive that maintains the baseline vaginal pH environment and SOLOSEC (secnidazole) which is used to treat bacterial vaginosis in women and the STI trichomoniasis in both men and women.

Website: evofem.com
Social
Email ID: *****@evofem.com
Phone Number: +1 **********
Registered Address: 12400 High Bluff Dr. Suite 600 San Diego, CA 92130

Key Metrics

Founded Year

2009

Location

San Diego, United States

Stage

Public

Total Funding

$100M in 15 rounds

Latest Funding Round

Post IPO, Jun 26, 2025, $*****

Investors

Invesco Mutual Fund & 11 more

Ranked

3^rd among 125 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

BioNTech & 158 more

Exit Details

Public

View Evofem's full profile

Evofem is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Evofem Biosciences, Inc. CIN: 20-8527075 , United States, Active	Jan 31, 2007	$10M - $50M (As on Dec 31, 2025)	33 (As on Aug 31, 2025)	-

Evofem got listed on Nov 21, 2014.

Click here to take a look at Evofem's IPO in detail

Evofem has raised a total funding of $100M over 15 rounds. Its first funding round was on Dec 08, 2009. Evofem has 9 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Evofem:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 26, 2025	4096900	Post IPO	8452968	5613858	9700972	2418882
Apr 08, 2025	6609521	Post IPO	9496034	7200174	1989455	7667885
Sep 27, 2023	7627154	Post IPO	1984560	6885338	2373030	6504360

Access funding benchmarks and valuations. Sign up today!

View details of Evofem's funding rounds and investors

Evofem's employee count trend

Evofem has 10 - 49 employees as of Mar 26. Here is Evofem's employee count trend over the years:

Uncover Evofem's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evofem include BioNTech, Insmed and Basilea. Here is the list of Top 10 competitors of Evofem, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
2nd	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
3rd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	Invesco Mutual Fund, Walleye & 10 others	65/100
4th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
5th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100
6th	Eubiologics 2012, Seoul (South Korea), Public	Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems.	$7.5M	IMM Investment, Global Health Investment Fund ... & 8 others	56/100
7th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	55/100
8th	Minervax 2010, Hellerup (Denmark), Series C	Developer of vaccines against life-threatening infections in newborns	$197M	Orbimed, EQT & 14 others	54/100
9th	Prokarium 2012, London (United Kingdom), Series C	Developer of bacterial immunotherapy treatments for various types of cancer	$70M	Korea Investment Holdings, Riyadh Valley Company ... & 9 others	52/100
10th	Aridis Pharma 2005, San Jose (United States), Public	Provider of human monoclonal antibodies against infectious diseases	$42.1M	Cystic Fibrosis Foundation, Lynx Financial ... & 5 others	51/100